EB1, in a dose-dependent manner (1.3-40 μM; 24 hours), inhibits the phosphorylation of eIF4E[1].
At doses of 2.5-40 μM (72 hours), EB1 exhibits dose-dependent cytotoxicity against tumor cells and induces apoptosis[1].
When directly acting on MNK kinase at concentrations of 5 μM, 10 μM, and 20 μM (24 hours), EB1 does not interfere with the activation of upstream signals such as p38 activation (p-p38) and the phosphorylation of its downstream effector HSP27[1].
Compound 14 (EB1) inhibits cancer cells HepG2 and MCF-7 with IC50 values of 0.74 μM and 5.18 μM, respectively[2].